SOPH

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: PHR DH NRC TBRG EVH OMCL WAY TDOC DOCS HQY

| Held by: ONEQ MEDI GNMX

Scroll to Statements

Index	-
Market Cap	474.01M
Enterprise Value	471.04M
Income	-80.94M
Sales	81.18M
Book/sh	0.64
Cash/sh	0.78
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	415
IPO	Jul 23, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	5.84
P/B	8.88
P/C	7.25
P/FCF	-
EV/EBITDA	-
EV/Sales	5.80
Quick Ratio	1.90
Current Ratio	2.06
Debt/Eq	1.37
LT Debt/Eq	1.31
Option/Short	Yes / Yes

EPS (ttm)	-1.18
EPS next Y	-0.66
EPS next Q	-0.23
EPS this Y	25.85%
EPS next Y	24.50%
EPS next 5Y	27.28%
EPS past 3/5Y	5.00% -13.68%
Sales past 3/5Y	17.56% 22.16%
EPS Y/Y TTM	-18.60%
Sales Y/Y TTM	20.85%
EPS Q/Q	-4.42%
Sales Q/Q	21.99%
Earnings	May 05 BMO
EPS/Sales Surpr.	-16.13% 6.29%

Insider Own	32.87%
Insider Trans	-1.63%
Inst Own	29.13%
Inst Trans	10.28%
ROA	-53.30%
ROE	-123.28%
ROIC	-76.79%
Gross Margin	67.28%
Oper. Margin	-87.66%
Profit Margin	-99.70%
SMA20	3.96%
SMA50	9.20%
SMA200	17.16%
Trades

Shs Outstand	71.79M
Shs Float	56.32M
Short Float	1.13%
Short Ratio	3.29
Short Interest	0.64M
52W High	6.30 -10.32%
52W Low	2.92 93.49%
Volatility	6.78% 7.32%
ATR (14)	0.38
RSI (14)	56.22
Beta	0.96
Rel Volume	1.63
Avg Volume	193.38K
Volume	314,363

Perf Week	5.61%
Perf Month	4.63%
Perf Quarter	19.45%
Perf Half Y	13.00%
Perf YTD	20.99%
Perf Year	50.67%
Perf 3Y	27.25%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	8.00
Prev Close	5.82
Price	5.65
Change	-2.92%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-24	Initiated	Craig Hallum	Buy	$11
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$10 → $5
Jun-27-24	Initiated	Guggenheim	Buy	$6
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$8
Jul-05-23	Resumed	JP Morgan	Overweight	$10
Jan-03-23	Initiated	BTIG Research	Buy	$6
Nov-23-22	Initiated	Credit Suisse	Neutral	$2
Oct-15-21	Resumed	Cowen	Outperform
Aug-17-21	Initiated	Morgan Stanley	Overweight	$24
Aug-17-21	Initiated	JP Morgan	Overweight	$23
Aug-17-21	Initiated	Credit Suisse	Outperform	$22
Aug-17-21	Initiated	Cowen	Outperform

Show Previous Ratings

Jun-22-26 08:25AM	SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting (PR Newswire)
Jun-19-26 08:00AM	SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jun-16-26 09:21PM	SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares (PR Newswire) +6.29%
04:20PM	SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares (PR Newswire)
Jun-10-26 08:00AM	SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting (PR Newswire)
08:00AM	Loading…
Jun-04-26 08:00AM	SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center (PR Newswire)
May-13-26 05:00AM	Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K. (PR Newswire)
May-05-26 04:54PM	SOPHiA GENETICS S.A. Q1 2026 Earnings Call Summary (Moby)
06:45AM	SOPHiA GENETICS Reports First Quarter 2026 Results (PR Newswire)
Apr-21-26 08:00AM	SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026 (PR Newswire)
Apr-16-26 08:00AM	Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026 (PR Newswire)
Mar-04-26 08:02PM	Sophia Genetics SA (SOPH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Mar-03-26 01:30PM	SOPHiA GENETICS Q4 Earnings Call Highlights (MarketBeat) -11.26%
12:34PM	SOPHiA GENETICS S.A. Q4 2025 Earnings Call Summary (Moby)
06:45AM	SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results (PR Newswire)
08:00AM	Loading…
Feb-25-26 08:00AM	SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference (PR Newswire)
Feb-18-26 09:41AM	Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy? (Zacks)
Feb-17-26 08:00AM	SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026 (PR Newswire)
Feb-10-26 09:22AM	SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems (PR Newswire)
Jan-12-26 07:00AM	SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan (PR Newswire)
Jan-07-26 08:00AM	SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology (PR Newswire)
Dec-12-25 10:15AM	AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave (PR Newswire)
Nov-25-25 07:46AM	Tempus AI's Data Business Is Expanding and Adding to Revenues: Here's How (Zacks)
Nov-11-25 09:00AM	SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine (PR Newswire) +6.21%
08:01AM	SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine (PR Newswire)
Nov-08-25 08:00PM	Sophia Genetics SA (SOPH) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... (GuruFocus.com)
Nov-04-25 06:45AM	SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance (PR Newswire) -6.40%
Nov-03-25 08:04AM	Earnings To Watch: Sophia Genetics SA (SOPH) Reports Q3 2025 Result (GuruFocus.com)
Oct-21-25 08:00AM	SOPHiA GENETICS to Announce Financial Results for Third Quarter 2025 on November 4, 2025 (PR Newswire)
Oct-20-25 09:03AM	Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy? (Zacks)
11:00AM	Loading…
Oct-16-25 11:00AM	A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in Japan (PR Newswire)
04:01AM	SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology (PR Newswire)
Sep-23-25 08:01AM	Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy (PR Newswire)
Sep-22-25 08:00AM	SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer (PR Newswire) +18.37%
Sep-08-25 05:36AM	Jessa Ziekenhuis to adopt SOPHiA GENETICS platform for cancer care (Hospital Management)
Sep-05-25 04:00AM	SOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership from the European Congress of Pathology (PR Newswire)
Aug-19-25 09:33AM	Strategic Partnerships Power Tempus AI's Healthcare Expansion (Zacks)
Aug-13-25 03:00PM	Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold? (Zacks)
Aug-06-25 11:01AM	Sophia Genetics SA (SOPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -7.95%
Aug-05-25 06:45AM	SOPHiA GENETICS Reports Second Quarter 2025 Results (PR Newswire)
06:40AM	SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes (PR Newswire)
Aug-04-25 10:07AM	Sophia Genetics SA (SOPH) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-01-25 03:00PM	Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy? (Zacks)
Jul-22-25 08:00AM	SOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025 (PR Newswire)
Jul-17-25 03:00PM	TEM Shares Surge on New AI Breakthrough: Should Investors Jump In? (Zacks)
Jun-09-25 03:00PM	Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today? (Zacks) -8.63%
May-15-25 03:00PM	After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order? (Zacks)
May-07-25 03:06AM	Sophia Genetics SA (SOPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ... (GuruFocus.com)
May-06-25 07:55AM	SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:45AM	SOPHiA GENETICS Reports First Quarter 2025 Results (PR Newswire)
May-05-25 10:19AM	Earnings To Watch: Sophia Genetics SA (SOPH) Reports Q1 2025 Result (GuruFocus.com)
Apr-28-25 03:00PM	Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings? (Zacks)
12:23PM	SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR (PR Newswire)
Apr-25-25 04:49AM	The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS (Zacks)
Apr-24-25 03:00PM	Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal? (Zacks)
Apr-22-25 08:00AM	SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025 (PR Newswire)
Apr-08-25 02:00AM	Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM Platform and its Liquid Biopsy Capabilities (PR Newswire)
Apr-01-25 03:00PM	Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock? (Zacks)
Mar-21-25 12:00PM	SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-18-25 09:00AM	SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC (PR Newswire)
Mar-05-25 02:04AM	Sophia Genetics SA (SOPH) Q4 2024 Earnings Call Highlights: Record Customer Growth Amidst ... (GuruFocus.com)
Mar-04-25 07:55AM	SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -13.17%
06:45AM	SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results (PR Newswire)
Mar-03-25 07:21AM	What To Expect From Sophia Genetics SA (SOPH) Q4 2024 Earnings (GuruFocus.com)
Feb-24-25 04:03AM	Leading Healthcare Institutions Adopt MSK-ACCESS for Liquid Biopsy Testing (PR Newswire)
Feb-18-25 08:30AM	SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025 (PR Newswire) +11.22%
Jan-28-25 08:59AM	SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities (PR Newswire)
Nov-21-24 05:30AM	SOPHiA GENETICS Launches MSK-IMPACT powered with SOPHiA DDM at AMP 2024 (PR Newswire)
Nov-06-24 06:59AM	SOPHiA GENETICS Faces Financial Challenges Amid Losses (TipRanks) -9.33%
02:08AM	Sophia Genetics SA (SOPH) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
12:10AM	Q3 2024 Sophia Genetics SA Earnings Call (Thomson Reuters StreetEvents)
Nov-05-24 06:32AM	SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer (PR Newswire)
06:30AM	SOPHiA GENETICS Reports Third Quarter 2024 Results (PR Newswire)
Nov-04-24 09:57AM	SOPHiA GENETICS SA (SOPH): A Bull Case Theory (Insider Monkey)
07:13AM	Sophia Genetics SA (SOPH) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-22-24 06:45AM	SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024 (PR Newswire)
Sep-14-24 09:00AM	SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024 (PR Newswire)
Sep-12-24 07:00AM	SOPHiA GENETICS Announces Poster Presentations at ESMO 2024 (PR Newswire)
04:00AM	SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024 (PR Newswire)
Sep-11-24 07:33AM	Sophia Genetics and AstraZeneca collaborate to expand liquid biopsy test rollout (Medical Device Network) +8.70%
Sep-10-24 10:28AM	SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing (PR Newswire)
Sep-05-24 08:30AM	SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024 (PR Newswire) +5.59%
Sep-04-24 06:00AM	SOPHiA GENETICS Unveils New Generation of the SOPHiA DDMTM Platform at Morgan Stanley Healthcare Conference 2024 (PR Newswire)
Aug-28-24 01:30PM	SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth Conference (PR Newswire) +5.26%
Aug-14-24 09:13AM	Sophia Genetics secures CE mark for DDM analytics platform under EUs IVDR (Medical Device Network)
03:00AM	SOPHiA DDM Platform Certified Under IVDR (PR Newswire)
Aug-12-24 09:35AM	SOPHiA GENETICS (SOPH) Loses -30.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-09-24 12:00PM	What Makes SOPHiA GENETICS (SOPH) a New Buy Stock (Zacks)
Aug-06-24 07:55AM	SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:45AM	SOPHiA GENETICS Reports Second Quarter 2024 Results (PR Newswire)
Jul-29-24 10:30AM	SOPHiA GENETICS Announces L'hpital Universitaire Avicenne is Live on SOPHiA DDM (PR Newswire)
Jul-24-24 11:59AM	SOPHIA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix (PR Newswire)
Jul-23-24 06:45AM	SOPHiA GENETICS to Announce Financial Results for Second Quarter 2024 on August 6, 2024 (PR Newswire)
Jul-05-24 04:32AM	Indias Dhiti Omics deploys SOPHiA DDM platform for solid tumour testing (Medical Device Network)
Jul-04-24 02:30AM	India-Based Dhiti Omics is Now Live on SOPHiA DDM (PR Newswire)
Jun-24-24 09:47AM	SOPHiA GENETICS Publishes Results of 2024 Annual General Meeting (GlobeNewswire)
02:00AM	SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application (PR Newswire)
Jun-13-24 06:00AM	SOPHiA GENETICS Announces Kepler Uniklinikum is Live on SOPHiA DDM Platform (PR Newswire)
May-30-24 12:39PM	SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care (PR Newswire)
May-29-24 10:00AM	SOPHiA GENETICS to Launch New Whole Genome Sequencing Capabilities (PR Newswire)

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Ph.D.Dr. Jurgi Camblong M.B.A.

Executive VP & CFOMr. George A. Cardoza M.B.A.

EVP & Chief Technology OfficerMr. Abhimanyu Verma

Executive VP & Chief Scientific OfficerDr. Zhenyu Xu Ph.D.

Head of Strategy and Investor RelationsKellen Sanger

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Camblong Jurgi	Executive Chairman	Jul 07 '26	Sale	5.28	17,685	93,327	3,541,122	Jul 08 04:01 PM
JURGI CAMBLONG	Director	Jul 07 '26	Proposed Sale	5.34	24,290	129,709		Jul 07 04:40 PM
CARDOZA GEORGE	Chief Financial Officer	Jul 06 '26	Sale	5.29	1,592	8,419	309,092	Jul 07 04:04 PM
Valente Manuela	Chief People Officer	Jul 06 '26	Sale	5.05	4,241	21,430	210,450	Jul 07 04:03 PM
Verma Abhimanyu	Chief Technology Officer	Jul 06 '26	Sale	5.10	5,285	26,957	192,171	Jul 07 04:03 PM
Xu Zhenyu	Chief Scientific Officer	Jul 06 '26	Sale	5.17	7,393	38,242	614,887	Jul 07 04:03 PM
Muken Ross	Chief Executive Officer	Jul 06 '26	Sale	5.22	9,838	51,354	670,651	Jul 07 04:03 PM
Puylaert Kevin	Chief Sales Officer	Jul 06 '26	Sale	5.03	216	1,087	147,948	Jul 07 04:03 PM
Menu Philippe	Chief Medical Officer	Jul 06 '26	Sale	5.16	7,393	38,156	233,387	Jul 07 04:03 PM
Camblong Jurgi	Executive Chairman	Jul 06 '26	Sale	5.25	22,486	118,164	3,558,807	Jul 07 04:03 PM
PHILIPPE MENU	Officer	Jul 06 '26	Proposed Sale	5.35	32,393	173,303		Jul 06 04:42 PM
ZHENYU XU	Officer	Jul 06 '26	Proposed Sale	5.35	19,393	103,753		Jul 06 04:42 PM
GEORGE CARDOZA	Officer	Jul 06 '26	Proposed Sale	5.35	1,592	8,517		Jul 06 04:39 PM
ROSS J MUKEN	Officer	Jul 06 '26	Proposed Sale	5.35	9,838	52,633		Jul 06 04:31 PM
MANUELA VALENTE	Officer	Jul 06 '26	Proposed Sale	5.35	4,241	22,689		Jul 06 04:27 PM
Camblong Jurgi	Executive Chairman	Jun 30 '26	Option Exercise	3.16	45,419	143,524	3,646,562	Jul 01 04:03 PM
Camblong Jurgi	Executive Chairman	Jun 29 '26	Option Exercise	3.16	18,060	57,070	3,619,553	Jul 01 04:03 PM
Camblong Jurgi	Executive Chairman	Jun 30 '26	Sale	6.11	65,269	398,632	3,581,293	Jul 01 04:03 PM
Camblong Jurgi	Executive Chairman	Jun 29 '26	Sale	5.87	18,410	108,058	3,601,143	Jul 01 04:03 PM
JURGI CAMBLONG	Director	Jun 30 '26	Proposed Sale	5.98	70,000	418,600		Jun 30 04:32 PM
JURGI CAMBLONG	Director	Jun 29 '26	Proposed Sale	5.75	20,000	115,000		Jun 29 04:45 PM
Camblong Jurgi	Chief Executive Officer	Jun 26 '26	Option Exercise	3.16	31,940	100,930	3,633,433	Jun 29 04:07 PM
Camblong Jurgi	Chief Executive Officer	Jun 26 '26	Sale	5.80	50,069	290,329	3,601,493	Jun 29 04:07 PM
Camblong Jurgi	Chief Executive Officer	Jun 25 '26	Sale	5.70	1,373	7,826	3,619,622	Jun 29 04:07 PM
JURGI CAMBLONG	Director	Jun 26 '26	Proposed Sale	5.69	68,129	387,654		Jun 26 04:31 PM
Verma Abhimanyu	Chief Technology Officer	Jun 25 '26	Sale	5.51	6,944	38,229	197,456	Jun 26 04:03 PM
Menu Philippe	Chief Medical Officer	Jun 25 '26	Sale	5.50	5,000	27,524	240,780	Jun 26 04:03 PM
JURGI CAMBLONG	Director	Jun 25 '26	Proposed Sale	5.52	1,373	7,579		Jun 25 04:31 PM
CARDOZA GEORGE	Chief Financial Officer	Jun 22 '26	Sale	5.38	774	4,164	310,684	Jun 23 04:01 PM
Muken Ross	President	Jun 22 '26	Sale	5.38	422	2,270	680,489	Jun 23 04:01 PM
GEORGE CARDOZA	Officer	Jun 22 '26	Proposed Sale	5.46	774	4,226		Jun 22 04:49 PM
ROSS J MUKEN	Officer	Jun 22 '26	Proposed Sale	5.46	422	2,304		Jun 22 04:47 PM
Xu Zhenyu	Chief Scientific Officer	Jun 15 '26	Sale	5.01	4,000	20,056	622,280	Jun 17 04:02 PM
Menu Philippe	Chief Medical Officer	Jun 12 '26	Sale	4.95	5,000	24,752	245,780	Jun 15 04:13 PM
Camblong Jurgi	Chief Executive Officer	Jun 10 '26	Sale	5.24	8,500	44,501	3,620,995	Jun 11 04:05 PM
CARDOZA GEORGE	Chief Financial Officer	Jun 05 '26	Buy	4.95	20,000	99,000	311,458	Jun 05 04:02 PM
Menu Philippe	Chief Medical Officer	May 26 '26	Sale	4.95	5,000	24,774	250,780	Jun 01 07:38 AM
Muken Ross	President	May 19 '26	Sale	4.60	761	3,501	680,911	May 20 04:03 PM
Xu Zhenyu	Chief Scientific Officer	May 19 '26	Sale	4.60	608	2,798	626,280	May 20 04:02 PM
Camblong Jurgi	Chief Executive Officer	May 19 '26	Sale	4.60	4,486	20,658	3,629,495	May 20 04:02 PM
Menu Philippe	Chief Medical Officer	May 19 '26	Sale	4.61	608	2,800	255,780	May 20 04:02 PM
Van Well Daan	Chief Legal Officer	May 19 '26	Sale	4.60	684	3,149	345,052	May 20 04:02 PM
Valente Manuela	Chief People Officer	May 19 '26	Sale	4.60	380	1,747	214,691	May 20 04:02 PM
Puylaert Kevin	Chief Sales Officer	May 19 '26	Sale	4.54	33	150	148,164	May 20 04:02 PM
JURGI CAMBLONG	Director	May 19 '26	Proposed Sale	4.69	12,986	60,904		May 19 04:34 PM
MANUELA VALENTE	Officer	May 19 '26	Proposed Sale	4.69	380	1,782		May 19 04:34 PM
PHILIPPE MENU	Officer	May 19 '26	Proposed Sale	4.69	15,608	73,202		May 19 04:33 PM
ROSS J MUKEN	Officer	May 19 '26	Proposed Sale	4.69	761	3,569		May 19 04:32 PM
DAAN GUIDO MARIA VAN WELL	Officer	May 19 '26	Proposed Sale	4.69	684	3,208		May 19 04:32 PM
ZHENYU XU	Officer	May 19 '26	Proposed Sale	4.69	4,608	21,612		May 19 04:32 PM
Xu Zhenyu	Chief Scientific Officer	May 13 '26	Sale	4.54	4,000	18,168	626,888	May 14 04:01 PM
HIBBS KATHY L	Director	May 12 '26	Sale	4.67	7,508	35,037	89,768	May 13 04:01 PM
Menu Philippe	Chief Medical Officer	May 12 '26	Sale	4.67	5,000	23,344	256,388	May 13 04:01 PM
Camblong Jurgi	Chief Executive Officer	May 11 '26	Sale	5.09	8,500	43,241	3,633,981	May 12 04:01 PM
Menu Philippe	Chief Medical Officer	Apr 27 '26	Sale	4.82	5,000	24,089	261,388	Apr 28 04:03 PM
Valente Manuela	Chief People Officer	Apr 20 '26	Sale	5.20	380	1,977	215,071	Apr 21 04:04 PM
Xu Zhenyu	Chief Scientific Officer	Apr 20 '26	Sale	5.21	608	3,165	630,888	Apr 21 04:04 PM
Van Well Daan	Chief Legal Officer	Apr 20 '26	Sale	5.20	684	3,554	345,736	Apr 21 04:04 PM
Camblong Jurgi	Chief Executive Officer	Apr 20 '26	Sale	5.21	4,486	23,350	3,642,481	Apr 21 04:04 PM
Menu Philippe	Chief Medical Officer	Apr 20 '26	Sale	5.20	608	3,162	266,388	Apr 21 04:04 PM
Muken Ross	President	Apr 20 '26	Sale	5.20	760	3,955	681,672	Apr 21 04:04 PM
Puylaert Kevin	Chief Sales Officer	Apr 20 '26	Sale	5.08	33	168	148,197	Apr 21 04:04 PM
PHILIPPE MENU	Officer	Apr 20 '26	Proposed Sale	5.28	10,608	56,010		Apr 20 04:32 PM
JURGI CAMBLONG	Director	Apr 20 '26	Proposed Sale	5.28	12,986	68,566		Apr 20 04:32 PM
MANUELA VALENTE	Officer	Apr 20 '26	Proposed Sale	5.28	380	2,006		Apr 20 04:32 PM
ZHENYU XU	Officer	Apr 20 '26	Proposed Sale	5.28	4,608	24,330		Apr 20 04:32 PM
ROSS J MUKEN	Officer	Apr 20 '26	Proposed Sale	5.28	760	4,013		Apr 20 04:32 PM
DAAN GUIDO MARIA VAN WELL	Officer	Apr 20 '26	Proposed Sale	5.28	684	3,612		Apr 20 04:29 PM
Xu Zhenyu	Chief Scientific Officer	Apr 14 '26	Sale	4.97	600	2,980	631,496	Apr 16 04:03 PM
Camblong Jurgi	Chief Executive Officer	Apr 14 '26	Sale	4.96	43,129	213,834	3,664,440	Apr 16 04:03 PM
Camblong Jurgi	Chief Executive Officer	Apr 15 '26	Sale	5.00	17,473	87,402	3,646,967	Apr 16 04:03 PM
Menu Philippe	Chief Medical Officer	Apr 14 '26	Sale	4.96	1,600	7,933	266,996	Apr 16 04:03 PM
Muken Ross	President	Apr 14 '26	Sale	4.96	2,800	13,887	682,432	Apr 16 04:03 PM
Van Well Daan	Chief Legal Officer	Apr 10 '26	Sale	4.67	2,400	11,201	346,420	Apr 14 04:02 PM
Xu Zhenyu	Chief Scientific Officer	Apr 13 '26	Sale	4.76	4,414	21,027	632,096	Apr 14 04:02 PM
Xu Zhenyu	Chief Scientific Officer	Apr 10 '26	Sale	4.68	3,706	17,347	636,510	Apr 14 04:02 PM
Camblong Jurgi	Chief Executive Officer	Apr 10 '26	Sale	4.72	12,232	57,711	3,711,968	Apr 14 04:02 PM
Camblong Jurgi	Chief Executive Officer	Apr 13 '26	Sale	4.76	4,399	20,957	3,707,569	Apr 14 04:02 PM
Muken Ross	President	Apr 13 '26	Sale	4.76	4,442	21,166	685,232	Apr 14 04:02 PM
Muken Ross	President	Apr 10 '26	Sale	4.69	3,687	17,279	689,674	Apr 14 04:02 PM
Menu Philippe	Chief Medical Officer	Apr 13 '26	Sale	4.76	4,400	20,962	268,596	Apr 14 04:01 PM
Menu Philippe	Chief Medical Officer	Apr 10 '26	Sale	4.68	3,725	17,441	272,996	Apr 14 04:01 PM
Camblong Jurgi	Chief Executive Officer	Apr 08 '26	Sale	4.84	2,800	13,553	3,726,150	Apr 10 04:02 PM
Camblong Jurgi	Chief Executive Officer	Apr 09 '26	Sale	4.74	1,950	9,244	3,724,200	Apr 10 04:02 PM
Muken Ross	President	Apr 08 '26	Sale	4.84	2,786	13,488	695,311	Apr 10 04:02 PM
Muken Ross	President	Apr 09 '26	Sale	4.74	1,950	9,239	693,361	Apr 10 04:02 PM
Xu Zhenyu	Chief Scientific Officer	Apr 08 '26	Sale	4.84	2,800	13,549	642,152	Apr 10 04:02 PM
Xu Zhenyu	Chief Scientific Officer	Apr 09 '26	Sale	4.74	1,936	9,176	640,216	Apr 10 04:02 PM
Menu Philippe	Chief Medical Officer	Apr 08 '26	Sale	4.84	2,800	13,544	278,652	Apr 10 04:02 PM
Menu Philippe	Chief Medical Officer	Apr 09 '26	Sale	4.74	1,931	9,152	276,721	Apr 10 04:02 PM
Valente Manuela	Chief People Officer	Apr 08 '26	Sale	4.85	3,824	18,543	215,451	Apr 10 04:02 PM
Van Well Daan	Chief Legal Officer	Apr 08 '26	Sale	4.85	2,861	13,862	350,808	Apr 10 04:02 PM
Van Well Daan	Chief Legal Officer	Apr 09 '26	Sale	4.74	1,988	9,424	348,820	Apr 10 04:02 PM
CARDOZA GEORGE	Chief Financial Officer	Apr 08 '26	Sale	4.85	1,403	6,801	291,458	Apr 10 04:02 PM
GEORGE CARDOZA	Officer	Apr 08 '26	Proposed Sale	4.90	1	5		Apr 08 04:37 PM
Menu Philippe	Chief Medical Officer	Apr 06 '26	Sale	4.85	2,700	13,096	283,852	Apr 08 04:05 PM
Menu Philippe	Chief Medical Officer	Apr 07 '26	Sale	4.87	2,400	11,677	281,452	Apr 08 04:05 PM
Puylaert Kevin	Chief Sales Officer	Apr 06 '26	Sale	4.86	624	3,032	148,230	Apr 08 04:05 PM
Van Well Daan	Chief Legal Officer	Apr 06 '26	Sale	4.86	2,705	13,136	356,069	Apr 08 04:04 PM
Van Well Daan	Chief Legal Officer	Apr 07 '26	Sale	4.87	2,400	11,682	353,669	Apr 08 04:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SOPHiA Genetics SA

Upgrade your Finviz experience